| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
For certain patients not able to undergo traditional tissue-based biopsy, liquid biopsy testing can provide fast, accurate answers. In some instances — such as when answers are needed more quickly than traditional biopsy allows, tissue is not available for molecular testing, tissue biopsy is not viable for the patient, and for patients with cancer in a difficult biopsy location — liquid biopsy testing can be a viable alternative.
Liquid Biopsy test menu
Faster and less invasive than traditional biopsy testing, our liquid biopsy panel is a cell-free DNA test that uses next-generation sequencing to evaluate peripheral blood for 33 genes. The genes included in our panel are a condensed yet comprehensive group of National Comprehensive Cancer Network (NCCN) Guidelines-targeted genes and genes associated with approved FDA therapies.
We require a DNA input of 20 nanograms, divided into two Streck tubes with 10 nanograms each. This lower input requirement may lead to lower sample rejection rates. This test also includes a detailed result report containing information on medications to guide treatment.
Key testing
Advantages
Highlights
Dr. Dong Chen and Dr. Sounak Gupta joined the “Becker’s Healthcare Podcast” to discuss the molecular testing space and its important role in personalized cancer treatment. Dr. Chen and Dr. Gupta highlighted the importance of selecting the right molecular tests for patients, the impact of genetic testing on cancer diagnosis and treatment, and how Mayo Clinic Laboratories is helping physicians make informed decisions for the best patient outcomes.
Gang Zheng, M.D., Ph.D., and Aaron Mansfield, M.D., describe Mayo Clinic Laboratories’ liquid biopsy, which analyzes blood samples for genetic information to guide cancer treatment. The circulating tumor DNA assay uses next generation sequencing and complements the laboratory's cell-based cancer testing.